Generic Launch By Indian Drug Maker Blocked By New Patent Move
This article was originally published in PharmAsia News
Executive Summary
India's Lupin may not be able to launch its generic version of the blood-pressure drug Altace (ramipril) in June as planned because of an action that could affect all Indian generics makers. Lupin had won its patent challenge against King Pharmaceuticals and Sanofi-Aventis, freeing it to market its generic when the patent expires June 7, but King has filed a citizen petition on a new patent. Other Indian drug makers have been assertive in trying to break patent protection in the United States, but the brand makers are fighting back. King's action requires an FDA review of the petition. (Click here for more
You may also be interested in...
Real World Data Failed To Impress Kaftrio’s European Reviewers
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic Clears Up Confusion Over Validity Of GMP Certificates
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
People On The Move: Appointments At Stada, PGEU, And UK Health Claims Committee
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.
Need a specific report? 1000+ reports available
Buy Reports